High-dose chemotherapy and autologous CD34-positive blood stem cell transplantation for multiple myeloma in an HIV carrier.
The epidemiology and clinical outcome of multiple myeloma in human immunodeficiency virus (HIV)-positive patients is poorly documented. There are uncertainties concerning the optimal management of this rare disorder. We report on the use of myeloablative chemotherapy with autologous stem cell transplantation in an HIV-positive patient with multiple myeloma.
Kentos
A
A
Clinique d'Hématologie, ULB-Hôpital Erasme, Free University of Brussels, Brussels, Belgium.
Vekemans
M
M
Van Vooren
J P
JP
Lambermont
M
M
Liesnard
C
C
Feremans
W
W
Farber
C M
CM
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000628:therapy; D000328:Adult; D018952:Antigens, CD34 / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017809:Fatal Outcome; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy* / Q000821:virology*; D014182:Transplantation, Autologous
D018952:Antigens, CD34